- Home
- SNTG vs CMND Comparison
SNTG vs CMND Comparison
Compare SNTG & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- CMND
- Stock Information
- Founded
- SNTG 2009
- CMND 2017
- Country
- SNTG China
- CMND Canada
- Employees
- SNTG N/A
- CMND N/A
- Industry
- SNTG Finance: Consumer Services
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- CMND Health Care
- Exchange
- SNTG Nasdaq
- CMND Nasdaq
- Market Cap
- SNTG 6.1M
- CMND 5.5M
- IPO Year
- SNTG 2021
- CMND N/A
- Fundamental
- Price
- SNTG $1.93
- CMND $1.34
- Analyst Decision
- SNTG
- CMND
- Analyst Count
- SNTG 0
- CMND 0
- Target Price
- SNTG N/A
- CMND N/A
- AVG Volume (30 Days)
- SNTG 8.7K
- CMND 160.9K
- Earning Date
- SNTG 12-20-2024
- CMND 11-26-2024
- Dividend Yield
- SNTG N/A
- CMND N/A
- EPS Growth
- SNTG N/A
- CMND N/A
- EPS
- SNTG N/A
- CMND N/A
- Revenue
- SNTG $146,554.00
- CMND N/A
- Revenue This Year
- SNTG N/A
- CMND N/A
- Revenue Next Year
- SNTG N/A
- CMND N/A
- P/E Ratio
- SNTG N/A
- CMND N/A
- Revenue Growth
- SNTG N/A
- CMND N/A
- 52 Week Low
- SNTG $1.47
- CMND $0.92
- 52 Week High
- SNTG $8.45
- CMND $6.80
- Technical
- Relative Strength Index (RSI)
- SNTG 33.98
- CMND 44.72
- Support Level
- SNTG $1.92
- CMND $1.33
- Resistance Level
- SNTG $2.19
- CMND $1.58
- Average True Range (ATR)
- SNTG 0.09
- CMND 0.11
- MACD
- SNTG -0.02
- CMND -0.01
- Stochastic Oscillator
- SNTG 16.37
- CMND 4.00
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.